1. Home
  2. NUAI vs PRTA Comparison

NUAI vs PRTA Comparison

Compare NUAI & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Era Energy & Digital Inc.

NUAI

New Era Energy & Digital Inc.

N/A

Current Price

$2.72

Market Cap

401.0M

Sector

Energy

ML Signal

N/A

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

N/A

Current Price

$8.50

Market Cap

429.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NUAI
PRTA
Founded
N/A
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
401.0M
429.2M
IPO Year
2024
2013

Fundamental Metrics

Financial Performance
Metric
NUAI
PRTA
Price
$2.72
$8.50
Analyst Decision
Strong Buy
Buy
Analyst Count
3
7
Target Price
$11.67
★ $21.40
AVG Volume (30 Days)
★ 9.8M
530.2K
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 1.89
N/A
EPS
N/A
★ 0.26
Revenue
★ $885,400.00
$814,000.00
Revenue This Year
N/A
$754.03
Revenue Next Year
$1,783.33
N/A
P/E Ratio
★ N/A
$34.04
Revenue Growth
★ 66.18
N/A
52 Week Low
$2.01
$7.73
52 Week High
$9.45
$11.80

Technical Indicators

Market Signals
Indicator
NUAI
PRTA
Relative Strength Index (RSI) 30.54 47.94
Support Level N/A $8.06
Resistance Level $5.52 $9.18
Average True Range (ATR) 0.39 0.39
MACD -0.03 0.06
Stochastic Oscillator 7.77 38.35

Price Performance

Historical Comparison
NUAI
PRTA

About NUAI New Era Energy & Digital Inc.

New Era Energy & Digital Inc is engaged into a fully integrated energy supplier delivering next-gen digital infrastructure and power assets. The company provides turnkey solutions to speed up data center deployment and reduce costs. The company focuses on future-proofing infrastructure for hyperscale, enterprise, and edge operators. The company provide integrated energy and digital solutions to support accelerating AI infrastructure deployment and optimize data center investments.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: